These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 35369761)
1. Small-molecule inhibitors of Slack potassium channels as potential therapeutics for childhood epilepsies. M Qunies A; A Emmitte K Pharm Pat Anal; 2022 Mar; 11(2):45-56. PubMed ID: 35369761 [TBL] [Abstract][Full Text] [Related]
2. Structure-Activity Relationship Studies in a Series of Xanthine Inhibitors of SLACK Potassium Channels. Qunies AM; Spitznagel BD; Du Y; Peprah PK; Mohamed YK; Weaver CD; Emmitte KA Molecules; 2024 May; 29(11):. PubMed ID: 38893312 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of a novel series of 1,2,4-oxadiazole inhibitors of SLACK potassium channels: Identification of in vitro tool VU0935685. Qunies AM; Spitznagel BD; Du Y; David Weaver C; Emmitte KA Bioorg Med Chem; 2023 Nov; 95():117487. PubMed ID: 37812884 [TBL] [Abstract][Full Text] [Related]
4. KCNT1-positive epilepsy of infancy with migrating focal seizures successfully treated with nonnarcotic antitussive drugs after treatment failure with quinidine: A case report. Takase C; Shirai K; Matsumura Y; Watanabe T; Watanabe A; Hirasawa-Inoue A; Mizuguchi T; Matsumoto N; Sugai K; Hayashi M Brain Dev; 2020 Sep; 42(8):607-611. PubMed ID: 32505479 [TBL] [Abstract][Full Text] [Related]
7. Early Treatment with Quinidine in 2 Patients with Epilepsy of Infancy with Migrating Focal Seizures (EIMFS) Due to Gain-of-Function KCNT1 Mutations: Functional Studies, Clinical Responses, and Critical Issues for Personalized Therapy. Dilena R; DiFrancesco JC; Soldovieri MV; Giacobbe A; Ambrosino P; Mosca I; Galli MA; Guez S; Fumagalli M; Miceli F; Cattaneo D; Darra F; Gennaro E; Zara F; Striano P; Castellotti B; Gellera C; Varesio C; Veggiotti P; Taglialatela M Neurotherapeutics; 2018 Oct; 15(4):1112-1126. PubMed ID: 30112700 [TBL] [Abstract][Full Text] [Related]
8. A quinidine non responsive novel KCNT1 mutation in an Indian infant with epilepsy of infancy with migrating focal seizures. Madaan P; Jauhari P; Gupta A; Chakrabarty B; Gulati S Brain Dev; 2018 Mar; 40(3):229-232. PubMed ID: 29037447 [TBL] [Abstract][Full Text] [Related]
9. An Epilepsy-Associated KCNT1 Mutation Enhances Excitability of Human iPSC-Derived Neurons by Increasing Slack K Quraishi IH; Stern S; Mangan KP; Zhang Y; Ali SR; Mercier MR; Marchetto MC; McLachlan MJ; Jones EM; Gage FH; Kaczmarek LK J Neurosci; 2019 Sep; 39(37):7438-7449. PubMed ID: 31350261 [TBL] [Abstract][Full Text] [Related]
10. Impaired motor skill learning and altered seizure susceptibility in mice with loss or gain of function of the Kcnt1 gene encoding Slack (K Quraishi IH; Mercier MR; McClure H; Couture RL; Schwartz ML; Lukowski R; Ruth P; Kaczmarek LK Sci Rep; 2020 Feb; 10(1):3213. PubMed ID: 32081855 [TBL] [Abstract][Full Text] [Related]
12. Discovery of the First Orally Available, Selective K Griffin AM; Kahlig KM; Hatch RJ; Hughes ZA; Chapman ML; Antonio B; Marron BE; Wittmann M; Martinez-Botella G ACS Med Chem Lett; 2021 Apr; 12(4):593-602. PubMed ID: 33859800 [TBL] [Abstract][Full Text] [Related]
13. New use for an old drug: quinidine in KCNT1-related epilepsy therapy. Liu R; Sun L; Wang Y; Wang Q; Wu J Neurol Sci; 2023 Apr; 44(4):1201-1206. PubMed ID: 36437393 [TBL] [Abstract][Full Text] [Related]
14. The Phe932Ile mutation in KCNT1 channels associated with severe epilepsy, delayed myelination and leukoencephalopathy produces a loss-of-function channel phenotype. Evely KM; Pryce KD; Bhattacharjee A Neuroscience; 2017 May; 351():65-70. PubMed ID: 28366665 [TBL] [Abstract][Full Text] [Related]
15. Disease-causing Slack potassium channel mutations produce opposite effects on excitability of excitatory and inhibitory neurons. Wu J; Quraishi IH; Zhang Y; Bromwich M; Kaczmarek LK Cell Rep; 2024 Mar; 43(3):113904. PubMed ID: 38457342 [TBL] [Abstract][Full Text] [Related]
16. Intolerance to quinidine in a n-of-1 trial for KCNT1 associated epilepsy of infancy with migrating focal seizures. Hughes E; Oates S; Pal DK Seizure; 2022 Dec; 103():46-50. PubMed ID: 36279596 [TBL] [Abstract][Full Text] [Related]
17. Characterization of two de novoKCNT1 mutations in children with malignant migrating partial seizures in infancy. Rizzo F; Ambrosino P; Guacci A; Chetta M; Marchese G; Rocco T; Soldovieri MV; Manocchio L; Mosca I; Casara G; Vecchi M; Taglialatela M; Coppola G; Weisz A Mol Cell Neurosci; 2016 Apr; 72():54-63. PubMed ID: 26784557 [TBL] [Abstract][Full Text] [Related]
18. In silico model reveals the key role of GABA in KCNT1-epilepsy in infancy with migrating focal seizures. Kuchenbuch M; Nabbout R; Yochum M; Sauleau P; Modolo J; Wendling F; Benquet P Epilepsia; 2021 Mar; 62(3):683-697. PubMed ID: 33617692 [TBL] [Abstract][Full Text] [Related]
19. Two Patients With KCNT1-Related Epilepsy Responding to Phenobarbital and Potassium Bromide. Datta AN; Michoulas A; Guella I; ; Demos M J Child Neurol; 2019 Oct; 34(12):728-734. PubMed ID: 31208268 [No Abstract] [Full Text] [Related]
20. KCNT1 epilepsy with migrating focal seizures shows a temporal sequence with poor outcome, high mortality and SUDEP. Kuchenbuch M; Barcia G; Chemaly N; Carme E; Roubertie A; Gibaud M; Van Bogaert P; de Saint Martin A; Hirsch E; Dubois F; Sarret C; Nguyen The Tich S; Laroche C; des Portes V; Billette de Villemeur T; Barthez MA; Auvin S; Bahi-Buisson N; Desguerre I; Kaminska A; Benquet P; Nabbout R Brain; 2019 Oct; 142(10):2996-3008. PubMed ID: 31532509 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]